Haleon PLC(HLN)
GBX --+0.00%
Reward56Moderate
Risk22Low
📊75%Data
HLN
+0.0 · +0.00%
GBX · LSE
Haleon PLC | Healthcare
Quality Compounder
Market Cap:33.53Bn
ℹ️
Reward Rating
56
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
22
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on HLN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 415p.

What is Haleon PLC?

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.

HLN · Verdict

Solid reward · low risk

HLN scores well on volatility and cash flow with no major weaknesses flagged in the model.

Based on 88% data coverage

HLN · Verdict

What’s working & what to watch

Strengths 3

  • Volatility95/100

    Top decile vs peers

  • Cash flow87/100

    18% free-cash-flow margin

  • Profitability78/100

    15% net margin · 9% ROE

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Haleon PLC?

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 33.53B, and a P/E ratio of 22.1x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (56)

The scoring profile indicates moderate reward potential, with profitability and growth as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap33.53B
P/E Ratio22.1471
Dividend Yield1.80%
52 Week High416.9293
52 Week Low274.4
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding9B
No. of Employees24,561
IndustryDrug Manufacturers - Specialty & Generic
ExchangeLSE
Beta0.23
CurrencyGBX